|
KMID : 0370220070510030186
|
|
Yakhak Hoeji
2007 Volume.51 No. 3 p.186 ~ p.193
|
|
|
Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention
|
|
Kim Jin-Hyun
Shin Sang-Jin
Kim Eun-Ju
Lee Young-Hee
|
|
|
Abstract
|
|
|
|
This study was performed to analyse the economic value of abciximab which is used in PCI to prevent high-risk patients with ischemic complications. The effectiveness of abciximab was extracted from published clinical trials by search-ing CCIS, and the direct medical costs relevant to using abciximab were estimated from the NHI claims database. The results in terms of cost per life-year gained (LYG) and cost per QALY gained showed that abciximab was cost-effective enough to deserve its cost. Social net benefit resulting from abciximab in PCI was estimated to be 60-70 billion Won per year.
|
|
|
KEYWORD
|
|
|
abciximab, cost-effectiveness analysis, cost-benefit analysis, PCI
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|